{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:10:39Z","timestamp":1779275439430,"version":"3.51.4"},"reference-count":134,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The rising costs, complexity, and ethical challenges of anticancer therapies have created an urgent need for structured frameworks to ensure clinical efficacy, cost-effectiveness, and equitable access. Oncology stewardship (OS) has emerged as a promising model to optimize oncology pharmacotherapy and resource allocation. However, the lack of a unified model for OS implementation and evaluation represents a critical gap. This review addresses this by synthesizing emerging practices and policy considerations to inform the structured integration of OS into oncology systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This narrative review followed the conceptual synthesis approach outlined by Baumeister &amp; Leary (1997) and Green et al. (2006), to develop a coherent understanding of OS as a clinical and policy framework. English-language sources published between 2001 and 2025 were purposively selected from PubMed, Scopus, and Google Scholar. Thematic analysis was used to organize and interpret findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five core domains were identified: (1) systemic drivers necessitating OS, including rising costs, drug shortages, safety concerns, and ethical considerations; (2) core operational strategies such as pre-authorization, dose optimization, site-of-care transitions, biosimilar adoption, and biomarker-guided therapy; (3) the governance role of Pharmacy and Therapeutics Committees in formulary management and clinical decision-making; (4) structural components and outcome metrics to assess the clinical, economic, and operational impact of OS; and (5) implementation barriers such as stakeholder resistance, limited infrastructure, and regulatory gaps. The review also highlights that although many OS initiatives demonstrate clinical and financial promise, their success is often limited by voluntary, fragmented implementation and a lack of standardized evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>OS offers a critical but underutilized framework for improving the quality, safety, and sustainability of oncology care. While several operational models and interventions have shown promise, their fragmented adoption and weak regulatory support hinder scalability. Advancing OS will require national-level policy integration, investment in implementation infrastructure, and the development of standardized metrics to guide evaluation and accountability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251372492","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T13:29:42Z","timestamp":1756474182000},"page":"691-708","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Oncology stewardship: A narrative review of principles and practices"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9296-8777","authenticated-orcid":false,"given":"Bushra","family":"Salman","sequence":"first","affiliation":[{"name":"National Hematology and Bone Marrow Transplant Center, University Medical City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5835-3167","authenticated-orcid":false,"given":"Amna","family":"Mohamed","sequence":"additional","affiliation":[{"name":"University of Technology and Applied Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Intisar","family":"Al-Riyami","sequence":"additional","affiliation":[{"name":"Sultan Qaboos University Hospital, University Medical City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Hamad","sequence":"additional","affiliation":[{"name":"National Center for Cancer Care & Research, Hamad Medical Corporation"},{"name":"College of Pharmacy, QU Health Sector, Qatar University, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2937-8838","authenticated-orcid":false,"given":"Murtadha","family":"Al-Khabori","sequence":"additional","affiliation":[{"name":"College of Medicine & Health Sciences, Sultan Qaboos University"},{"name":"Hematology and Bone Marrow Transplantation Department, University Medical City, Al-Seeb, Oman"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01300"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01677-0"},{"key":"e_1_3_3_4_2","article-title":"How to make evidence-based integrative medicine a part of everyday oncology practice","author":"Bao T","unstructured":"Bao T, Greenlee H, Lopez AM, et al. How to make evidence-based integrative medicine a part of everyday oncology practice. Am Soc Clin Oncol Educ Book [Internet] 2023 [cited 2025 Jun 23]: e389830. https:\/\/ascopubs.org\/doi\/10.1200\/EDBK_389830","journal-title":"Am Soc Clin Oncol Educ Book [Internet]"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01799"},{"key":"e_1_3_3_6_2","first-page":"107815522412652","article-title":"Oncology stewardship practice in the United States: a hematology\/oncology pharmacy association national survey","author":"Banez MT","unstructured":"Banez MT, Atienza S, Butts A, et al. Oncology stewardship practice in the United States: a hematology\/oncology pharmacy association national survey. J Oncol Pharm Pract [Internet] 2024 [cited 2025 Feb 21]: 10781552241265280. https:\/\/doi.org\/10.1177\/10781552241265280","journal-title":"J Oncol Pharm Pract [Internet]"},{"key":"e_1_3_3_7_2","first-page":"5232","article-title":"Advances in cancer therapy: clinical benefit of new cancer drugs","volume":"15","author":"Michaeli DT","year":"2023","unstructured":"Michaeli DT, Michaeli JC, Michaeli T. Advances in cancer therapy: clinical benefit of new cancer drugs. Aging 2023; 15: 5232\u20135234.","journal-title":"Aging"},{"key":"e_1_3_3_8_2","unstructured":"Antrim A. Pharmacy Times. Oncology Stewardship Can Take Multiple Forms in Practice. 2022 [cited 2025 Feb 24] https:\/\/www.pharmacytimes.com\/view\/oncology-stewardship-can-take-multiple-forms-in-practice"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04872-1"},{"key":"e_1_3_3_10_2","first-page":"147","article-title":"Development and implementation of an academic cancer therapy stewardship program","volume":"24","author":"Steinberg AS","year":"2018","unstructured":"Steinberg AS, Parikh AB, Kim S, et al. Development and implementation of an academic cancer therapy stewardship program. Am J Manag Care 2018; 24: 147\u2013151.","journal-title":"Am J Manag Care"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231154465"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1037\/1089-2680.1.3.311"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0899-3467(07)60142-6"},{"key":"e_1_3_3_14_2","unstructured":"Global Oncology Trends 2024: Outlook to 2028 [Internet]. [cited 2025 Mar 1] https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/global-oncology-trends-2024"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.03.28"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-023-01320-4"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2047536"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7826"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.1229"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01451"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00518-0"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00545"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.4745"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00948-1"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.2023.19.11_suppl.212"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00463-0"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09706-y"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00470-9"},{"key":"e_1_3_3_29_2","article-title":"Demystifying the WHO Model Lists of Essential Medicines for cancer care","author":"Trapani D","unstructured":"Trapani D, de Vries EGE. Demystifying the WHO Model Lists of Essential Medicines for cancer care. Lancet Oncol [Internet] 2025 [cited 2025 Jun 24]. https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(25)00270-0\/abstract","journal-title":"Lancet Oncol [Internet]"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)00151-X"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxrep.2025.102035"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90403-3"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr416"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2014.34.e146"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.130"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100739"},{"key":"e_1_3_3_37_2","article-title":"The patient experience of prior authorization for cancer care","volume":"6","author":"Chino F","unstructured":"Chino F, Baez A, Elkins IB, et al. The patient experience of prior authorization for cancer care. JAMA Netw Open [Internet] 2023 [cited 2025 Feb 23]; 6: e2338182. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10585404\/","journal-title":"JAMA Netw Open [Internet]"},{"key":"e_1_3_3_38_2","article-title":"Impact of prior authorization on patient access to cancer care","author":"Trapani D","unstructured":"Trapani D, Kraemer L, Rugo HS, et al. Impact of prior authorization on patient access to cancer care. Am Soc Clin Oncol Educ Book [Internet] 2023 [cited 2025 Feb 21]: e100036. https:\/\/ascopubs.org\/doi\/10.1200\/EDBK_100036","journal-title":"Am Soc Clin Oncol Educ Book [Internet]"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa157"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.1531"},{"key":"e_1_3_3_41_2","first-page":"1","article-title":"Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm","volume":"14","author":"Pawlyn C","unstructured":"Pawlyn C, Schjesvold FH, Cairns DA, et al. Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood Cancer J [Internet] 2024 [cited 2025 Feb 23]; 14: 1\u20138. https:\/\/www.nature.com\/articles\/s41408-024-01109-4","journal-title":"Blood Cancer J [Internet]"},{"key":"e_1_3_3_42_2","unstructured":"NCCN. Guidelines Process. Development and Update of Guidelines. 2025 [cited 2025 Feb 23] https:\/\/www.nccn.org\/guidelines\/guidelines-process\/development-and-update-of-guidelines"},{"key":"e_1_3_3_43_2","article-title":"Dose rounding of biologic and cytotoxic anticancer agents: a position statement of the hematology\/oncology pharmacy association","volume":"14","author":"Fahrenbruch R","unstructured":"Fahrenbruch R, Kintzel P, Bott AM, et al. Dose rounding of biologic and cytotoxic anticancer agents: a position statement of the hematology\/oncology pharmacy association. J Oncol Pract [Internet] 2018 [cited 2025 Feb 21]; 14: e130\u2013e136.","journal-title":"J Oncol Pract [Internet]"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.357"},{"key":"e_1_3_3_45_2","first-page":"29","article-title":"Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital","volume":"8","author":"Chiumente M","unstructured":"Chiumente M, Russi A, Todino F, et al. Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital. Glob Reg Health Technol Assess [Internet] 2021 [cited 2025 Feb 23]; 8: 29\u201334. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9616189\/","journal-title":"Glob Reg Health Technol Assess [Internet]"},{"key":"e_1_3_3_46_2","article-title":"National health service England introduces dose banding","volume":"17","author":"Mayor S","unstructured":"Mayor S. National health service England introduces dose banding. Lancet Oncol [Internet] 2016 [cited 2025 Feb 23]; 17: e271. https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(16)30199-1\/fulltext","journal-title":"Lancet Oncol [Internet]"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217736376"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15702"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1159\/000534011"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210366171"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214533369"},{"key":"e_1_3_3_52_2","unstructured":"Counce J. INFUSION. Home Infusion\u2019s Expanding Role in Optimizing Site of Care. 2019 [cited 2025 Feb 23] https:\/\/nhia.org\/documents\/CE_May_June_2019.pdf"},{"key":"e_1_3_3_53_2","unstructured":"ASHP. Navigating and Optimizing Infusion Services when Hospital-based Care is Not an Option [Internet]. 2019 [cited 2025 Feb 23] https:\/\/www.ashp.org\/-\/media\/assets\/practice-management\/docs\/Site-of-Care-Challenges-81919.pdf"},{"key":"e_1_3_3_54_2","article-title":"Cost differential of immuno-oncology therapy delivered at community versus hospital clinics","volume":"25","author":"Gordan L","unstructured":"Gordan L, Blazer M, Saundankar V, et al. Cost differential of immuno-oncology therapy delivered at community versus hospital clinics. Am J Manag Care 2019 [cited 2025 Feb 23]; 25. https:\/\/www.ajmc.com\/view\/cost-differential-of-immunooncology-therapy-delivered-at-community-versus-hospital-clinics","journal-title":"Am J Manag Care"},{"key":"e_1_3_3_55_2","article-title":"Differences in health care use and costs among patients with cancer receiving intravenous chemotherapy in physician offices versus in hospital outpatient settings","volume":"13","author":"Fisher MD","unstructured":"Fisher MD, Punekar R, Yim YM, et al. Differences in health care use and costs among patients with cancer receiving intravenous chemotherapy in physician offices versus in hospital outpatient settings. J Oncol Pract [Internet] 2017 [cited 2025 Feb 23]; 13: e37\u2013e46.","journal-title":"J Oncol Pract [Internet]"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7290.826"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1335344"},{"key":"e_1_3_3_58_2","first-page":"387","article-title":"Cancer patient-centered home care: a new model for health care in oncology","volume":"7","author":"Tralongo P","unstructured":"Tralongo P, Ferra\u00f9 F, Borsellino N, et al. Cancer patient-centered home care: a new model for health care in oncology. Ther Clin Risk Manag [Internet] 2011 [cited 2025 Feb 23]; 7: 387\u2013392.","journal-title":"Ther Clin Risk Manag [Internet]"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2969"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.09.007"},{"key":"e_1_3_3_61_2","first-page":"81","article-title":"Economic implications of step-down outpatient management for fever and neutropenia episodes in pediatric cancer patients: a cost minimization analysis","volume":"24","author":"Avil\u00e9s-Robles MJ","unstructured":"Avil\u00e9s-Robles MJ, Reyes-L\u00f3pez A. Economic implications of step-down outpatient management for fever and neutropenia episodes in pediatric cancer patients: a cost minimization analysis. BMC Health Serv Res [Internet]. 2024 [cited 2025 Feb 23]; 24: 81.","journal-title":"BMC Health Serv Res [Internet]"},{"key":"e_1_3_3_62_2","unstructured":"HOPA. Site of Care Issue Brief [Internet]. 2024 [cited 2025 Feb 23] https:\/\/www.hoparx.org\/documents\/289\/Site_of_Care_Issue_Brief_-_Updated_02.22.24.pdf"},{"key":"e_1_3_3_63_2","unstructured":"ASHP. Impact of Site of Care Trends: An Introduction and Strategy to Identify the Issues [Internet]. 2018 [cited 2025 Feb 23] https:\/\/www.ashp.org\/-\/media\/assets\/pharmacy-practice\/resource-centers\/practice-management\/Impact-to-site-of-care-trends.ashx"},{"key":"e_1_3_3_64_2","unstructured":"Yim S. FDA. FDA. Updated FDA Labeling Recommendations for Biosimilar and Interchangeable Biosimilar Products. 2024 [cited 2025 Feb 24] https:\/\/www.fda.gov\/drugs\/our-perspective\/updated-fda-labeling-recommendations-biosimilar-and-interchangeable-biosimilar-products"},{"key":"e_1_3_3_65_2","unstructured":"APhA. Focus on Interchangeable Biosimilars [Internet]. 2024 [cited 2025 Feb 24] https:\/\/biosimilarscouncil.org\/wp-content\/uploads\/2024\/08\/22354-Focus-on-Interchangeable-Biosimilars.pdf"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.9095"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7532"},{"key":"e_1_3_3_68_2","first-page":"688","article-title":"Integrating biosimilars into oncology practice: implications for the advanced practitioner","volume":"8","author":"Campen CJ","unstructured":"Campen CJ. Integrating biosimilars into oncology practice: implications for the advanced practitioner. J Adv Pract Oncol [Internet] 2017 [cited 2025 Feb 24]; 8: 688\u2013699. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6188098\/","journal-title":"J Adv Pract Oncol [Internet]"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.18305"},{"key":"e_1_3_3_70_2","first-page":"3","article-title":"Biosimilar cost savings in the United States","volume":"7","author":"Mulcahy AW","unstructured":"Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States. Rand Health Q [Internet] 2018 [cited 2025 Feb 24]; 7: 3. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6075809\/","journal-title":"Rand Health Q [Internet]"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00771"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxab080"},{"key":"e_1_3_3_73_2","first-page":"160","article-title":"Precision oncology: who, how, what, when, and when not?","author":"Schwartzberg L","unstructured":"Schwartzberg L, Kim ES, Liu D, et al. Precision oncology: who, how, what, when, and when not? Am Soc Clin Oncol Educ Book [Internet] 2017 [cited 2025 Feb 25]: 160\u2013169. https:\/\/ascopubs.org\/doi\/10.1200\/EDBK_174176","journal-title":"Am Soc Clin Oncol Educ Book [Internet]"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020242"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102019"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051196"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040812"},{"key":"e_1_3_3_78_2","first-page":"429","article-title":"Global challenges in access to and implementation of precision oncology: the health care manager and health economist perspective","author":"Shih YCT","unstructured":"Shih YCT, Pan IW, Teich N. Global challenges in access to and implementation of precision oncology: the health care manager and health economist perspective. Am Soc Clin Oncol Educ Book [Internet] 2022 [cited 2025 May 17]: 429\u2013437. https:\/\/ascopubs.org\/doi\/full\/10.1200\/EDBK_359650","journal-title":"Am Soc Clin Oncol Educ Book [Internet]"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114225"},{"key":"e_1_3_3_80_2","article-title":"Supporting biomarker-driven therapies in oncology: a genomic testing cost calculator","volume":"28","author":"Stenzinger A","unstructured":"Stenzinger A, Cuffel B, Paracha N, et al. Supporting biomarker-driven therapies in oncology: a genomic testing cost calculator. The Oncologist [Internet] 2023 [cited 2025 May 17]; 28: e242\u2013e253. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10166172\/","journal-title":"The Oncologist [Internet]"},{"key":"e_1_3_3_81_2","first-page":"403","article-title":"Biomarker testing for personalized therapy in lung cancer in low- and middle-income countries","author":"Hirsch FR","unstructured":"Hirsch FR, Zaric B, Rabea A, et al. Biomarker testing for personalized therapy in lung cancer in low- and middle-income countries. Am Soc Clin Oncol Educ Book [Internet] 2017 [cited 2025 May 17]: 403\u2013408. https:\/\/ascopubs.org\/doi\/10.1200\/EDBK_175243","journal-title":"Am Soc Clin Oncol Educ Book [Internet]"},{"issue":"15","key":"e_1_3_3_82_2","article-title":"Real-world biomarker testing practices in cancer treatment in a lower-middle income country in Southeast Asia","volume":"38","author":"Catedral LIG","unstructured":"Catedral LIG, Tan HN, Chua AV, et al. Real-world biomarker testing practices in cancer treatment in a lower-middle income country in Southeast Asia. J Clin Oncol [Internet]. 2020 [cited 2025 May 17]; 38(15_suppl): e19042\u2013e19042.","journal-title":"J Clin Oncol [Internet]"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.5868"},{"key":"e_1_3_3_84_2","article-title":"Characteristics of cost-effectiveness studies for oncology drugs approved in the United States from 2015-2020","volume":"4","author":"Haslam A","unstructured":"Haslam A, Lythgoe MP, Greenstreet Akman E, et al. Characteristics of cost-effectiveness studies for oncology drugs approved in the United States from 2015-2020. JAMA Netw Open [Internet] 2021 [cited 2025 Feb 24]; 4: e2135123.","journal-title":"JAMA Netw Open [Internet]"},{"key":"e_1_3_3_85_2","article-title":"The bar is high: evaluating fit-for-use oncology real-world data for regulatory decision making","author":"Lerro CC","unstructured":"Lerro CC, Bradley MC, Forshee RA, et al. The bar is high: evaluating fit-for-use oncology real-world data for regulatory decision making. JCO Clin Cancer Inform [Internet] 2024 [cited 2025 Feb 24]: e2300261. https:\/\/ascopubs.org\/doi\/10.1200\/CCI.23.00261","journal-title":"JCO Clin Cancer Inform [Internet]"},{"key":"e_1_3_3_86_2","first-page":"1","article-title":"Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy?","author":"Renner A","unstructured":"Renner A, Burotto M, Rojas C. Immune checkpoint inhibitor dosing: can we go lower without compromising clinical efficacy? J Glob Oncol [Internet] 2019 [cited 2025 Feb 24]: 1\u20135. https:\/\/ascopubs.org\/doi\/10.1200\/JGO.19.00142","journal-title":"J Glob Oncol [Internet]"},{"key":"e_1_3_3_87_2","article-title":"Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab","volume":"23","author":"Malmberg R","unstructured":"Malmberg R, Zietse M, Dumoulin DW, et al. Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. Lancet Oncol [Internet] 2022 [cited 2025 Feb 24]; 23: e552\u2013e561. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S147020452200554X","journal-title":"Lancet Oncol [Internet]"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01182-3"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12140"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0105"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182240"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.12.018"},{"key":"e_1_3_3_93_2","unstructured":"Bath C. The ASCO Post. MSKCC\u2019s Decision Not to Purchase New Cancer Drug Sparks Editorial and Unprecedented Actions. 2012 [cited 2025 Feb 24] https:\/\/ascopost.com\/issues\/december-15-2012\/mskcc-s-decision-not-to-purchase-new-cancer-drug-sparks-editorial-and-unprecedented-actions\/"},{"key":"e_1_3_3_94_2","unstructured":"Hernandez R. Pharmacy Times. Sanofi Halves the Price of Zaltrap in Response to Criticism from Oncologists. 2012 [cited 2025 Feb 24] https:\/\/www.pharmacytimes.com\/view\/sanofi-halves-the-price-of-zaltrap-in-response-to-criticism-from-oncologists"},{"key":"e_1_3_3_95_2","first-page":"293","article-title":"P&T committee drug prioritization criteria: a tool developed by a Saudi health care system","volume":"43","author":"Esba LCA","year":"2018","unstructured":"Esba LCA, Almodaimegh H, Alhammad A, et al. P&T committee drug prioritization criteria: a tool developed by a Saudi health care system. P T Peer-Rev J Formul Manag 2018; 43: 293\u2013300.","journal-title":"P T Peer-Rev J Formul Manag"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1332"},{"key":"e_1_3_3_97_2","volume-title":"Improving healthcare quality in Europe: Characteristics, effectiveness and implementation of different strategies [Internet] [Internet]","author":"Panteli D","unstructured":"Panteli D, Legido-Quigley H, Reichebner C, et al. Clinical Practice Guidelines as a quality strategy. In: Busse R, Klazinga N, Panteli D, Quentin W (eds) Improving healthcare quality in Europe: Characteristics, effectiveness and implementation of different strategies [Internet] [Internet]. Copenhagen: European Observatory on Health Systems and Policies, 2019 [cited 2025 Mar 8]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK549283\/"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.020"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.015396"},{"key":"e_1_3_3_100_2","unstructured":"HOPA. Core Competency Program [Internet]. 2023 [cited 2025 Aug 11] https:\/\/www.hoparx.org\/hopa-learn\/core-competency-program\/"},{"key":"e_1_3_3_101_2","unstructured":"HOPA. Toolkit for Access Representation and Opportunity [Internet]. 2023 [cited 2025 Aug 11] https:\/\/www.hoparx.org\/about-us\/access-representation-opportunity-at-hopa\/aro-toolkit\/"},{"key":"e_1_3_3_102_2","unstructured":"ISOPP. ISOPP Oncology Pharmacy Service [Internet]. 2025 [cited 2025 Aug 11] https:\/\/www.isopp.org\/library\/isopp-oncology-pharmacy-service-levels"},{"key":"e_1_3_3_103_2","unstructured":"ISOPP. Toolkits [Internet]. 2025 [cited 2025 Aug 11] https:\/\/www.isopp.org\/library\/toolkits"},{"key":"e_1_3_3_104_2","unstructured":"American Society of Clinical Oncology (ASCO). ASCO Value Framework [Internet]. 2020 [cited 2024 Jan 2] https:\/\/old-prod.asco.org\/news-initiatives\/current-initiatives\/cancer-care-initiatives\/value-cancer-care"},{"key":"e_1_3_3_105_2","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)","author":"Cherny NI","unstructured":"Cherny NI, Oosting SF, Dafni U, et al. ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0). Ann Oncol [Internet] 2025 May 22 [cited 2025 Jun 21]. https:\/\/www.annalsofoncology.org\/article\/S0923-7534(25)00166-8\/fulltext","journal-title":"Ann Oncol [Internet]"},{"issue":"6","key":"e_1_3_3_106_2","article-title":"Value frameworks for the patient-provider interaction: a comparison of the ASCO value framework versus NCCN evidence blocks in determining value in oncology","volume":"23","author":"Shah-Manek B","unstructured":"Shah-Manek B, Galanto JS, Nguyen H, et al. Value frameworks for the patient-provider interaction: a comparison of the ASCO value framework versus NCCN evidence blocks in determining value in oncology. J Manag Care Spec Pharm [Internet]. 2017 [cited 2025 Jun 21]; 23(6-a Suppl): S13\u2013S20.","journal-title":"J Manag Care Spec Pharm [Internet]"},{"key":"e_1_3_3_107_2","unstructured":"ICER. Evidence Rating Matrix [Internet]. 2023 [cited 2025 Mar 17] https:\/\/icer.org\/evidence-rating-matrix\/"},{"key":"e_1_3_3_108_2","first-page":"107815522412521","article-title":"Evaluating the clinical benefit of pembrolizumab as a first-line agent in advanced solid tumors: a comprehensive review","author":"Mohamed A","year":"2024","unstructured":"Mohamed A, Salman B, Shaikh AJ. Evaluating the clinical benefit of pembrolizumab as a first-line agent in advanced solid tumors: a comprehensive review. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract 2024: 10781552241252100.","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"key":"e_1_3_3_109_2","first-page":"253","article-title":"Value frameworks in oncology: comparative analysis and implications to the pharmaceutical industry","volume":"10","author":"Slomiany M","year":"2017","unstructured":"Slomiany M, Madhavan P, Kuehn M, et al. Value frameworks in oncology: comparative analysis and implications to the pharmaceutical industry. Am Health Drug Benefits 2017; 10: 253\u2013260.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_3_110_2","article-title":"Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries: a WHO practical toolkit","volume":"1","author":"WHO","unstructured":"WHO. Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries: a WHO practical toolkit. JAC-Antimicrob Resist [Internet] 2019 [cited 2025 Feb 24]; 1: dlz072.","journal-title":"JAC-Antimicrob Resist [Internet]"},{"key":"e_1_3_3_111_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/10463356.2019.1681232","article-title":"Chemotherapy Stewardship","volume":"34","author":"McBride A","unstructured":"McBride A. Chemotherapy Stewardship. Oncol Issues [Internet] 2019 [cited 2025 Feb 24]; 34: 3\u20133.","journal-title":"Oncol Issues [Internet]"},{"key":"e_1_3_3_112_2","article-title":"Implementation of a pharmacy-managed program for the transition of chemotherapy to the outpatient setting","volume":"75","author":"McBride A","unstructured":"McBride A, Campen CJ, Camamo J, et al. Implementation of a pharmacy-managed program for the transition of chemotherapy to the outpatient setting. Am J Health Syst Pharm [Internet] 2018 [cited 2025 Feb 24]; 75: e246\u2013e258.","journal-title":"Am J Health Syst Pharm [Internet]"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155221995539"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-016-0339-9"},{"key":"e_1_3_3_115_2","first-page":"004695802513358","article-title":"Improving clinical pharmacist performance in oncology care through education on pharmaceutical care plans documentation: a Pre-post interventional study","volume":"62","author":"Ali T","unstructured":"Ali T, Siddiqui A, Bhutta OA, et al. Improving clinical pharmacist performance in oncology care through education on pharmaceutical care plans documentation: a Pre-post interventional study. Inq J Med Care Organ Provis Financ [Internet] 2025 [cited 2025 Jun 24]; 62: 00469580251335819. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC12078956\/","journal-title":"Inq J Med Care Organ Provis Financ [Internet]"},{"key":"e_1_3_3_116_2","article-title":"The Power in Patient Education: A Collaborative Approach to Cancer Care","volume":"1","author":"Singhi E","year":"2025","unstructured":"Singhi E, Lucas A. The Power in Patient Education: A Collaborative Approach to Cancer Care. Adv Cancer Educ Qual Improv [Internet] 2025; 1(. https:\/\/openworks.mdanderson.org\/aceqi\/vol1\/iss1\/9","journal-title":"Adv Cancer Educ Qual Improv [Internet]"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1089\/tmj.2011.0182"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231184779"},{"key":"e_1_3_3_119_2","first-page":"1296","article-title":"Oncology training and education initiatives in low and middle income countries: a scoping review","volume":"15","author":"Karim S","unstructured":"Karim S, Sunderji Z, Jalink M, et al. Oncology training and education initiatives in low and middle income countries: a scoping review. Ecancermedicalscience [Internet] 2021 [cited 2025 Jun 24]; 15: 1296. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8580602\/","journal-title":"Ecancermedicalscience [Internet]"},{"key":"e_1_3_3_120_2","first-page":"107815522513302","article-title":"Updated definition and components for oncology stewardship in healthcare systems","author":"Pathak N","unstructured":"Pathak N, Sapkota S, Wangge G, et al. Updated definition and components for oncology stewardship in healthcare systems. J Oncol Pharm Pract [Internet] 2025 [cited 2025 Jun 24]: 10781552251330241. https:\/\/doi.org\/10.1177\/10781552251330241","journal-title":"J Oncol Pharm Pract [Internet]"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.8736"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2018.05.008"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics5010005"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02399"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.2023.19.11_suppl.37"},{"key":"e_1_3_3_126_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-23-0119"},{"key":"e_1_3_3_127_2","unstructured":"ACSQHC. Fact sheet for prescribers and pharmacists: Real-time prescription monitoring: a digital tool for clinical safety. 2024."},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00640-3"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0066"},{"key":"e_1_3_3_130_2","article-title":"Reducing the cost of cancer care: how to bend the curve downward","volume":"32","author":"Smith TJ","unstructured":"Smith TJ, Hillner BE, Kelly RJ. Reducing the cost of cancer care: how to bend the curve downward. Am Soc Clin Oncol Educ Book [Internet] 2012 [cited 2025 Feb 25]; 32: e46\u2013e51.","journal-title":"Am Soc Clin Oncol Educ Book [Internet]"},{"key":"e_1_3_3_131_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.975"},{"key":"e_1_3_3_132_2","article-title":"Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non\u2013Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care","author":"Temel JS","unstructured":"Temel JS, Greer JA, Admane S, et al. Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non\u2013Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care. J Clin Oncol [Internet] 2011 [cited 2025 Feb 25]. https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2010.32.4459","journal-title":"J Clin Oncol [Internet]"},{"key":"e_1_3_3_133_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.1474"},{"key":"e_1_3_3_134_2","article-title":"Delivery of financial navigation services within national cancer institute\u2013designated cancer centers","volume":"5","author":"De Moor JS","unstructured":"De Moor JS, Mollica M, Sampson A, et al. Delivery of financial navigation services within national cancer institute\u2013designated cancer centers. JNCI Cancer Spectr [Internet] 2021 [cited 2025 Feb 25]; 5: pkab033. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8242138\/","journal-title":"JNCI Cancer Spectr [Internet]"},{"key":"e_1_3_3_135_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz036"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251372492","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251372492","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251372492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:56:01Z","timestamp":1779274561000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251372492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":134,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/10781552251372492"],"URL":"https:\/\/doi.org\/10.1177\/10781552251372492","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]}}}